Sanjay Singh Biography and Net Worth

Executive Vice President, Technical Operations of MannKind

Sanjay Singh is Executive Vice President of MannKind’s Technical Operations, leading our Danbury facility including oversight of our commercial and contract manufacturing. With more than 30 years of experience in pharmaceutical technical operations, he has worked with multiple technologies, delivery systems, and therapeutic areas.

What is Sanjay R. Singh's net worth?: The estimated net worth of Sanjay R. Singh is at least $2.63 million as of November 14th, 2025. Mr. Singh owns 455,211 shares of MannKind stock worth more than $2,631,120 as of February 6th. This net worth estimate does not reflect any other investments that Mr. Singh may own. Additionally, Mr. Singh receives an annual salary of $364,530.00 as Executive Vice President, Technical Operations at MannKind. Learn More about Sanjay R. Singh's net worth.
How old is Sanjay R. Singh?: Mr. Singh is currently 58 years old. There are 8 older executives and no younger executives at MannKind. The oldest executive at MannKind is Mr. John F. Bedard, Senior Vice President of Worldwide Regulatory Affairs, who is 74 years old. Learn More on Sanjay R. Singh's age.
What is Sanjay R. Singh's salary?: As the Executive Vice President, Technical Operations of MannKind Corporation, Mr. Singh earns $364,530.00 per year. There are 7 executives that earn more than Mr. Singh. The highest earning executive at MannKind is Dr. Michael E. Castagna Pharm.D., CEO & Director, who commands a salary of $1,530,000.00 per year. Learn More on Sanjay R. Singh's salary.
How do I contact Sanjay R. Singh?: The corporate mailing address for Mr. Singh and other MannKind executives is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. MannKind can also be reached via phone at (818) 661-5000 and via email at [email protected]. Learn More on Sanjay R. Singh's contact information.
Has Sanjay R. Singh been buying or selling shares of MannKind?: Sanjay R. Singh has not been actively trading shares of MannKind in the last ninety days. Most recently, Sanjay R. Singh sold 18,777 shares of the business's stock in a transaction on Friday, November 14th. The shares were sold at an average price of $5.03, for a transaction totalling $94,448.31. Following the completion of the sale, the executive vice president now directly owns 455,211 shares of the company's stock, valued at $2,289,711.33. Learn More on Sanjay R. Singh's trading history.
Who are MannKind's active insiders?: MannKind's insider roster includes Steven Binder (CFO), Michael Castagna (CEO), Alejandro Galindo (Insider), Sanjay Singh (Executive Vice President, Technical Operations), David Thomson (EVP), and Stuart Tross (Insider). Learn More on MannKind's active insiders.
Are insiders buying or selling shares of MannKind?: In the last twelve months, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 594,821 shares worth more than $3,035,512.44. The most recent insider tranaction occured on January, 8th when insider Stuart A Tross sold 47,006 shares worth more than $297,547.98. Insiders at MannKind own 2.7% of the company. Learn More about insider trades at MannKind.
Information on this page was last updated on 1/8/2026.

Sanjay R. Singh Insider Trading History at MannKind

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/14/2025	Sell	18,777	$5.03	$94,448.31	455,211

Sanjay R. Singh Buying and Selling Activity at MannKind

MannKind Company Overview

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Today's Range

Now: $5.78

$5.53

$5.86

50 Day Range

MA: $5.74

$5.21

$6.21

2 Week Range

Now: $5.78

$3.38

$6.51

Volume

3,011,867 shs

Average Volume

3,993,371 shs

Market Capitalization

$1.77 billion

P/E Ratio

57.80

Dividend Yield

N/A

Beta

0.84

Sanjay Singh Biography and Net Worth

What is Sanjay R. Singh's net worth?

How old is Sanjay R. Singh?

What is Sanjay R. Singh's salary?

How do I contact Sanjay R. Singh?

Has Sanjay R. Singh been buying or selling shares of MannKind?

Who are MannKind's active insiders?

Are insiders buying or selling shares of MannKind?